# Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer

> **NCT01262651** · PHASE3 · COMPLETED · sponsor: **GW Pharmaceuticals Ltd** · enrollment: 397 (actual)

## Conditions studied

- Pain
- Advanced Cancer

## Interventions

- **DRUG:** Nabiximols
- **DRUG:** Placebo (GA-0034)

## Key facts

- **NCT ID:** NCT01262651
- **Lead sponsor:** GW Pharmaceuticals Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11-25
- **Primary completion:** 2015-07-02
- **Final completion:** 2015-07-02
- **Target enrollment:** 397 (ACTUAL)
- **Last updated:** 2018-04-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01262651

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01262651, "Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT01262651. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*